Atara Biotherapeutics, Inc. — Form SCHEDULE 13D/A
Filed July 24, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D/A
— Neutral
significance 28/100
What the filing says
Redmile Group, LLC filed an amended Schedule 13D/A regarding beneficial ownership in Atara Biotherapeutics, Inc. on July 24, 2026. The filing document itself contains no substantive disclosures of specific share counts, percentages, dollar amounts, or material changes to ownership positions—only administrative metadata and filing headers are visible in the provided text.
Why this rating
Amendment to existing disclosure filing; no material ownership change, transaction amount, or strategic event disclosed in provided text. Routine SEC compliance filing.
See more from July 24, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.